Literature DB >> 26954620

Long-Term Results of Bilateral Medial Rectus Muscle Recession in Children with Developmental Delay.

Tzukit Zehavi-Dorin1, Itay Ben-Zion1, Eedy Mezer2, Tamara Wygnanski-Jaffe1.   

Abstract

PURPOSE: To assess the long-term results of a reduced amount of medial rectus recession in children with esotropia and developmental delay.
METHODS: A retrospective chart analysis of 42 children with developmental delay who had undergone surgery for esotropia during a 20-year period in a large referral center was performed. The pre- and postoperative angle of deviation was calculated for each subject as the mean of distant and near angles measured by a cover test or the Krimsky measurement. Surgical success was categorized as esotropia or exotropia of ≤10 prism diopters (PD). The main outcome measure was a stable surgical result after several years of follow-up.
RESULTS: The chart review identified 42 children who met inclusion criteria, with a mean age of 2.9 years (range, 0.8-10 years). The mean angle of esotropia prior to surgery was 44.29 ± 13.9 PD (range 20-80 PD). All patients had bilateral medial rectus muscle recessions, with a mean surgical dosage of 5.04 ± 0.62 mm per muscle, on average 0.66 mm less than the standard amount. The average postoperative follow-up was 4.6 years (median 3.67 years, range 8 months-15 years). Twenty-four children (57%) achieved surgical success, 13 (31%) were undercorrected, and 5 (12%) were overcorrected. Ten of the 18 with an unsuccessful surgical outcome underwent a second procedure. The overall surgical success rate for all patients after all procedures was 71%.
CONCLUSIONS: The main reason for surgical failure after bilateral medial rectus muscle recession (BMR) in developmentally delayed children remains residual esotropia. However, with time, more patients demonstrated consecutive exotropia. Although it is difficult to achieve a stable long-term ocular alignment in children with developmental delay, satisfactory results may be achieved with additional surgical procedures. The optimal amount of primary recession and whether to perform the surgical schedules according to the Parks tables or to reduce the amount of the recession when operating on children with developmental delay is still debatable.

Entities:  

Keywords:  BMR; cerebral palsy; consecutive exotropia; developmental delay; esotropia

Mesh:

Year:  2016        PMID: 26954620     DOI: 10.3109/09273972.2015.1130064

Source DB:  PubMed          Journal:  Strabismus        ISSN: 0927-3972


  6 in total

1.  Neural Plasticity Following Surgical Correction of Strabismus in Monkeys.

Authors:  Mythri Pullela; Mehmet N Agaoglu; Anand C Joshi; Sevda Agaoglu; David K Coats; Vallabh E Das
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-10-01       Impact factor: 4.799

Review 2.  Strabismus Surgery for Esotropia, Down Syndrome and Developmental Delay; Is an Altered Surgical Dose Required? A Literature Review.

Authors:  Alia Harrison; Louise Allen; Anna O'Connor
Journal:  Br Ir Orthopt J       Date:  2020-02-05

3.  Routine use of non-absorbable sutures in bi-medial rectus recession as a measure to reduce the incidence of consecutive exotropia.

Authors:  Biana Dubinsky-Pertzov; Adi Einan-Lifshitz; Eran Pras; Morris E Hartstein; Yair Morad
Journal:  Eye (Lond)       Date:  2021-08-09       Impact factor: 4.456

4.  Outcomes of esotropia surgery in Saudi Arabia: An audit from a single center.

Authors:  Lujain M Sulayem; Afaf A Bin-Khathlan
Journal:  Saudi J Ophthalmol       Date:  2018-08-04

5.  Strabismus surgery in Angelman syndrome: More than ocular alignment.

Authors:  Paola Michieletto; Stefano Pensiero; Laura Diplotti; Luca Ronfani; Manuela Giangreco; Alberto Danieli; Paolo Bonanni
Journal:  PLoS One       Date:  2020-11-13       Impact factor: 3.240

6.  LONG-TERM VARIABILITY OF STRABISMUS ANGLE IN NEUROLOGICALLY IMPAIRED PREMATURE INFANTS: A 12-YEAR FOLLOW UP.

Authors:  Ena Sardelić; Dobrila Karlica Utrobičić
Journal:  Acta Clin Croat       Date:  2019-09       Impact factor: 0.780

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.